Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.79 |
| ▸ | HTR2C | P28335 | 18/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166801 | 0.88 | HTR2A (1.00) | HTR2AHTR2C | |
| SCHEMBL14041176 | 0.88 | HTR2A (0.76) | HTR2AHTR2CKMT2A | |
| SCHEMBL15248576 | 0.88 | HTR2A (0.74) | HTR2AHTR2CKMT2A | |
| SCHEMBL5063227 | 0.85 | HTR2A (1.00) | HTR2AHTR2C | |
| SCHEMBL1166745 | 0.83 | HTR2A (0.78) | HTR2AHTR2C | |
| SCHEMBL29572894 | 0.83 | HTR2A (0.78) | HTR2AHTR2C | |
| SCHEMBL2065657 | 0.81 | HTR2A (0.60) | HTR2AHTR2CKMT2A | |
| SCHEMBL4660710 | 0.81 | HTR2A (0.74) | HTR2AHTR2C | |
| SCHEMBL6201643 | 0.81 | HTR2A (0.79) | HTR2AHTR2C | |
| SCHEMBL2063845 | 0.80 | KDM6B (0.55) | HTR2AHTR2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150073141-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-03-12 | — | — | US | claimed |
| US-8754238-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-17 | — | — | US | claimed |
| CN-1826322-B | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor for the prevention and treatment of related disorders | ARENA PHARM INC | 2012-04-18 | — | — | CN | claimed |
| CN-101875961-A | Be used to prevent and treat associated conditions and as the diaryl and the aryl heteroaryl urea derivatives of 5-HT2A serotonin receptor modulator | ARENA PHARM INC | 2010-11-03 | — | — | CN | claimed |
| CN-101871931-A | Be used to prevent and treat associated conditions and as the diaryl and the aryl heteroaryl urea derivatives of 5-HT2A serotonin receptor modulator | ARENA PHARM INC | 2010-10-27 | — | — | CN | claimed |
| US-20080200530-A1 | Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| CN-101160127-A | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT 2A serotonin receptor for the prevention or treatment of progressive multifocal leukoencephalopathy | ARENA PHARM INC (US) | 2008-04-09 | — | — | CN | claimed |
| EP-1843762-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS OR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | Arena Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20070078134-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| US-20070072857-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | claimed |
| EP-1695966-A1 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2006-08-30 | — | — | EP | claimed |
| CN-1826322-A | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT 2A serotonin receptor for the prevention and treatment of related disorders | ARENA PHARM INC (US) | 2006-08-30 | — | — | CN | claimed |
| WO-2006078610-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS OR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| EP-1558582-B1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-12-21 | — | — | EP | claimed |
| EP-1558582-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTIALS, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005012254-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | ARENA PHARMACEUTIALS, INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005012254-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080124-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885KMT2A 707/4885 |
| US-20080200530-A1 | Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 4/4885KMT2A 844/4885 |
| US-20070078134-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885KMT2A 707/4885 |
| US-20070072857-A1 | Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885KMT2A 707/4885 |
| US-20150073141-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HTR2A 2/4885HTR2C 3/4885KMT2A 1644/4885 |
| US-20230277505-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | HTR2A 2/4885HTR2C 3/4885KMT2A 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.